Objective To evaluate the clinical effect and safety of pramipexole in the treatment of motor complications in Parkinson's disease.Methods Ninety-two patients with advanced Parkinson's disease were randomly divided into treatment group (n=46) and control group (n=46). Madopar was administered in the control group, whereas the treatment group was given pramipexole in addition to the therapy for control group. The course of treatment was 12 weeks for both groups. Unified Parkinson's Disease Rating Scale (UPDRS) IV was used for evaluating the patients' conditions before treatment and at different time points during treatment, and the adverse events were recorded. The clinical effects were assessed after 12 weeks of treatment.Results After treatment, UPDRS IV score decreased compared with the baseline value in both groups, and the treatment group had a significantly more decrease than the control group (P<0.01). At the end of the 12-week treatment, the treatment group had significantly higher overall response rates than the control group in terms of wearing-off phenomenon (93.75% vs 70.59%, P<0.05), on-off phenomenon (91.67% vs 63.64%, P<0.05), and dyskinesia (84.62% vs 48.00%, P<0.05). There was no significant difference in the incidence of adverse events showed no significant difference between the two groups (P>0.05).Conclusions Pramipexole has good clinical effects and safety in the treatment of motor complications in Parkinson's disease.